[go: up one dir, main page]

CL2012003152A1 - Composicion farmaceutica para ser usada en terapia de reemplazo de glucocorticoides mediante la administracion oral una vez al dia de una dosis equivalente a la hidrocortizona de acuerdo con un nomograma de peso o un nomograma farmacocinetico; metodo de tratamiento; metodo para derivar una dosificacion individualizada. - Google Patents

Composicion farmaceutica para ser usada en terapia de reemplazo de glucocorticoides mediante la administracion oral una vez al dia de una dosis equivalente a la hidrocortizona de acuerdo con un nomograma de peso o un nomograma farmacocinetico; metodo de tratamiento; metodo para derivar una dosificacion individualizada.

Info

Publication number
CL2012003152A1
CL2012003152A1 CL2012003152A CL2012003152A CL2012003152A1 CL 2012003152 A1 CL2012003152 A1 CL 2012003152A1 CL 2012003152 A CL2012003152 A CL 2012003152A CL 2012003152 A CL2012003152 A CL 2012003152A CL 2012003152 A1 CL2012003152 A1 CL 2012003152A1
Authority
CL
Chile
Prior art keywords
nomogram
hydrocortizone
pharmacokinetic
derive
day
Prior art date
Application number
CL2012003152A
Other languages
English (en)
Inventor
Thomas Hedner
Ulrika Sigrida Helena Simonsson
Gudmundur Johannsson
Stanko Skrtic
Hans Lennernas
Original Assignee
Duocort Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42953726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012003152(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Duocort Pharma Ab filed Critical Duocort Pharma Ab
Publication of CL2012003152A1 publication Critical patent/CL2012003152A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composición farmacéutica para ser usada en terapia de reemplazo de glucocorticoides mediante la administración oral una vez al día de una dosis equivalente a la hidrocortizona de acuerdo con un nomograma de peso o un nomograma farmacocinético; método de tratamiento; método para derivar una dosificación individualizada.
CL2012003152A 2010-05-20 2012-11-09 Composicion farmaceutica para ser usada en terapia de reemplazo de glucocorticoides mediante la administracion oral una vez al dia de una dosis equivalente a la hidrocortizona de acuerdo con un nomograma de peso o un nomograma farmacocinetico; metodo de tratamiento; metodo para derivar una dosificacion individualizada. CL2012003152A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201000442 2010-05-20

Publications (1)

Publication Number Publication Date
CL2012003152A1 true CL2012003152A1 (es) 2013-07-12

Family

ID=42953726

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012003152A CL2012003152A1 (es) 2010-05-20 2012-11-09 Composicion farmaceutica para ser usada en terapia de reemplazo de glucocorticoides mediante la administracion oral una vez al dia de una dosis equivalente a la hidrocortizona de acuerdo con un nomograma de peso o un nomograma farmacocinetico; metodo de tratamiento; metodo para derivar una dosificacion individualizada.

Country Status (15)

Country Link
US (2) US20130209565A1 (es)
EP (1) EP2571505B1 (es)
JP (1) JP2013526552A (es)
KR (1) KR20130099815A (es)
CN (1) CN102933218A (es)
AU (1) AU2011254959A1 (es)
BR (1) BR112012029466A2 (es)
CA (1) CA2799820A1 (es)
CL (1) CL2012003152A1 (es)
CO (1) CO6660433A2 (es)
IL (1) IL223000A0 (es)
MX (1) MX337429B (es)
PE (1) PE20131024A1 (es)
SG (2) SG10201506611XA (es)
WO (1) WO2011144327A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401031D0 (sv) 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
GB201119985D0 (en) 2011-11-19 2012-01-04 Diurnal Ltd Treatment of adrenal insufficiency
US10262112B2 (en) * 2013-02-04 2019-04-16 Precera Bioscience, Inc. Prescription decision support system and method using comprehensive multiplex drug monitoring
GB201308933D0 (en) 2013-05-17 2013-07-03 Diurnal Ltd Paediatric composition
ES2967617T3 (es) * 2013-12-06 2024-05-03 Bioverativ Therapeutics Inc Herramientas de farmacocinética poblacional y sus usos
WO2016196687A1 (en) * 2015-06-01 2016-12-08 Massachusetts Institute Of Technology System and method for neuroendocrine control
CN107115308B (zh) * 2016-02-23 2021-02-23 天津金耀集团有限公司 一种氢化可的松双相缓释片剂组合物
CN108553436A (zh) * 2018-06-08 2018-09-21 华益药业科技(安徽)有限公司 一种20mg氢化可的松片处方和工艺规程
US12451248B2 (en) * 2018-08-17 2025-10-21 The Regents Of The University Of California Diagnosing hypoadrenocorticism from hematologic and serum chemistry parameters using machine learning algorithm

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119848D0 (en) * 2001-08-15 2001-10-10 Univ Sheffield Delayed and sustained drug release
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
WO2010115615A1 (en) * 2009-04-07 2010-10-14 Duocort Pharma Ab Improved glucocorticoid therapy

Also Published As

Publication number Publication date
PE20131024A1 (es) 2013-10-10
BR112012029466A2 (pt) 2017-03-01
IL223000A0 (en) 2013-02-03
MX2012013254A (es) 2013-01-24
SG10201506611XA (en) 2015-09-29
EP2571505A1 (en) 2013-03-27
EP2571505B1 (en) 2016-07-06
WO2011144327A1 (en) 2011-11-24
JP2013526552A (ja) 2013-06-24
US20130209565A1 (en) 2013-08-15
US20150209375A1 (en) 2015-07-30
CO6660433A2 (es) 2013-04-30
MX337429B (es) 2016-03-04
SG185457A1 (en) 2012-12-28
AU2011254959A1 (en) 2013-01-10
KR20130099815A (ko) 2013-09-06
CN102933218A (zh) 2013-02-13
CA2799820A1 (en) 2011-11-24

Similar Documents

Publication Publication Date Title
CL2012003152A1 (es) Composicion farmaceutica para ser usada en terapia de reemplazo de glucocorticoides mediante la administracion oral una vez al dia de una dosis equivalente a la hidrocortizona de acuerdo con un nomograma de peso o un nomograma farmacocinetico; metodo de tratamiento; metodo para derivar una dosificacion individualizada.
PE20170302A1 (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
ECSP14013217A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk.
EA201491285A1 (ru) Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
EA201590053A1 (ru) Модуляторы пути системы комплемента и их применение
MX360554B (es) Composiciones que comprenden y metodos que utilizan inhibidores de co-transportadores de glucosa-sodio 1 y 2.
MX368507B (es) Uso de un anticuerpo anti-pd-1 en combinación con un anticuerpo anti-ctla-4 en la manufactura de un medicamento para el tratamiento de cáncer.
MX2022013590A (es) Metodos y composiciones para el tratamiento de trastorno por deficit de atencion.
MX2013011655A (es) Forma de dosis unitaria para administracion oral.
BR112014032734A2 (pt) derivados de pirrolidina e seu uso como moduladores da série de reação de complemento
MX2015015223A (es) Administración local y concomitante de nanoportadores sintéticos, tolerogénicos para reducir la hipersensibilidad tipo i y tipo iv.
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
EA201491281A1 (ru) КОМПОЗИЦИЯ В ФОРМЕ СУХОГО ПОРОШКА, СОДЕРЖАЩАЯ КОРТИКОСТЕРОИД И β-АДРЕНЕРГИЧЕСКОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, ДЛЯ ВВЕДЕНИЯ ИНГАЛЯЦИЕЙ
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
PH12013500007A1 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
PE20120791A1 (es) Composiciones y metodos para terapia prolongada con aminopiridinas
NZ606964A (en) A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
BR112015007647A2 (pt) derivados de quetamina
EA201391689A1 (ru) Система доставки лекарственного средства
UA109803C2 (xx) (ПІРИДИН-4-ІЛ)БЕНЗИЛАМІДИ ЯК АЛОСТЕРИЧНІ МОДУЛЯТОРИ АЛЬФА-7 nAChR
EA201591415A1 (ru) Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии
AR088204A1 (es) Medicamentos para el tratamiento de la rinitis alergica que comprenden un antagonista de pgd2 y un antagonista de histamina